Europe - Frankfurt Stock Exchange - FRA:V3V - DE000A0BL849 - Common Stock
The current stock price of V3V.DE is 5.95 EUR. In the past month the price increased by 12.26%. In the past year, price increased by 45.12%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRE.DE | FRESENIUS SE & CO KGAA | 14.36 | 27.58B | ||
| FME.DE | FRESENIUS MEDICAL CARE AG | 10.42 | 22.99B | ||
| HI.MI | HEALTH ITALIA SPA | 18.26 | 56.24M | ||
| EUK.MI | EUKEDOS SPA | N/A | 16.03M |
FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. The company is headquartered in Leipzig, Sachsen and currently employs 771 full-time employees. The company went IPO on 2007-11-21. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The firm acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
FAMICORD AG
Perlickstrasse 5
Leipzig SACHSEN DE
Employees: 771
Phone: 49341487925500
FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. The company is headquartered in Leipzig, Sachsen and currently employs 771 full-time employees. The company went IPO on 2007-11-21. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The firm acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
The current stock price of V3V.DE is 5.95 EUR.
V3V.DE does not pay a dividend.
V3V.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
V3V.DE stock is listed on the Frankfurt Stock Exchange exchange.
FAMICORD AG (V3V.DE) has a market capitalization of 104.96M EUR. This makes V3V.DE a Micro Cap stock.
You can find the ownership structure of FAMICORD AG (V3V.DE) on the Ownership tab.
ChartMill assigns a technical rating of 10 / 10 to V3V.DE. When comparing the yearly performance of all stocks, V3V.DE is one of the better performing stocks in the market, outperforming 85.13% of all stocks.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed V3V.DE and the average price target is 7.65 EUR. This implies a price increase of 28.57% is expected in the next year compared to the current price of 5.95.